Study of Colorectal Cancer Screening Options

Part of paid clinical trials in Portland, Oregon.

Sponsor
Kaiser Permanente
Study ID
NCT05987709
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • GuardantSHIELD Blood Test — DIAGNOSTIC_TEST
    The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC

Study Details

The investigators propose to evaluate Guardant Health's commercially available colorectal cancer screening assay(Guardant SHIELD) in individuals who are not up to date with CRC screening.

Key Dates

Start date
Mar 17, 2022
Status verified
Dec 2025
Primary completion
Dec 31, 2022
Completion
Jun 15, 2023

Study Design

Enrollment
2,004 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING

Arms

  • Other: Guardant Shield Blood Test
    Patients will have the Guardant Shield blood test for colorectal cancer screening.
  • No Intervention: Standard of Care
    Patients will have standard of care, which is a reminder to do their FIT test for colorectal cancer screening

Primary Outcome Measure

Assess Colorectal Cancer Screening Completion [ Time Frame: Within 3 months of patient identification ]

Locations (1)

FacilityCityStateZIPSite coordinators
Kaiser Permanente NorthwestPortlandOregon97227-

Find similar trials in Portland, OR

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
Kaiser Permanente Northwest· Portland, OR

Related Studies